Quick Answer
Wegovy (semaglutide), a GLP-1 medication, and Zepbound (tirzepatide), a GIP/GLP-1 medication, can support chronic weight management in eligible adults who have obesity or overweight with a weight-related condition. That can include people in perimenopause or postmenopause. They are not treatments for menopause, low estrogen, hot flashes, or night sweats. Their FDA-approved uses are based on weight and health criteria, not menopausal status (Wegovy prescribing information; Zepbound prescribing information).
Research specific to menopause is still limited. Current evidence supports discussing GLP-1-based treatment for its approved metabolic indications while managing menopause symptoms, muscle, and bone health as related but separate issues.
Key Points
- Midlife weight change reflects aging, lifestyle, sleep, medications, and menopause-related changes in body composition; menopause is not the sole cause.
- Semaglutide and tirzepatide may help eligible adults lose weight, but neither replaces menopause treatment.
- A 2025 post hoc analysis found that tirzepatide reduced weight and waist measures versus placebo across presumed pre-, peri-, and postmenopausal groups, but reproductive stage was assigned retrospectively.
- Hormone therapy (HT or HRT) treats selected menopause symptoms and can help prevent bone loss in appropriate patients; it is not a weight-loss drug.
- There is no established evidence that GLP-1 medications treat hot flashes.
- Bone and muscle deserve extra attention during weight loss because lean mass can fall, and limited bone-specific evidence raises questions that larger studies still need to answer.
Evidence Snapshot
- In the 1,961-participant STEP 1 trial, semaglutide 2.4 mg plus lifestyle intervention produced a mean 14.9% weight reduction at 68 weeks, compared with 2.4% with placebo. This was an obesity trial, not a menopause trial (STEP 1, New England Journal of Medicine).
- A longitudinal SWAN analysis found that fat gain accelerated and lean mass declined during the menopause transition, while the rate of total weight gain did not accelerate at its start (JCI Insight).
- In a 2025 exploratory analysis of three SURMOUNT trials, tirzepatide reduced body weight, waist circumference, and waist-to-height ratio versus placebo across reproductive-stage groups. Most stages were inferred from age, and the analysis was not prespecified (Obesity).
- A small 2024 randomized trial in 64 adults at increased fracture risk found lower lumbar-spine and total-hip bone mass after 52 weeks of semaglutide 1.0 mg versus placebo. It was not an obesity-dose trial, and it was not large or long enough to determine fracture risk (eClinicalMedicine).
What Menopause Changes—and What It Does Not
The menopause transition can change body composition even when total body weight changes less dramatically. In the SWAN cohort, fat mass increased faster and lean mass began to decline around the transition. Total weight had already been rising before the transition and did not suddenly accelerate when menopause began.
That distinction matters. Statements such as “menopause slows metabolism” or “low estrogen causes weight gain” are too simple on their own. Aging, activity, sleep disruption, food intake, medications, and health conditions can all contribute. Menopause may shift where fat is stored and make preserving muscle more important, but an individual change on the scale cannot be assigned to hormones without a broader assessment.
Hot flashes and night sweats can also disrupt sleep. Poor sleep may make appetite, activity, and weight-management routines harder, but treating weight is not the same as treating vasomotor symptoms.
How GLP-1-Based Medicines May Fit
Appetite and weight management
Semaglutide, a GLP-1 medication, reduces appetite and energy intake. Tirzepatide activates both GIP and GLP-1 receptors. For adults who meet an approved indication, these medicines may be one part of long-term obesity care alongside nutrition, physical activity, and clinical follow-up.
The major semaglutide weight-loss result often quoted—about 15% at 68 weeks—comes from the overall STEP 1 population. It should not be presented as a menopause-specific result. Participants were not randomized or analyzed primarily by menopause status.
The newer tirzepatide analysis is more directly relevant. It found weight and waist reductions across presumed reproductive stages. Still, it was a post hoc analysis: the original trials did not prospectively collect menopause stage, and many participants were categorized mainly by age. It is reassuring evidence that response was not obviously limited to one reproductive stage, not proof that tirzepatide corrects a menopause-specific mechanism.
Blood sugar and abdominal fat
These medicines can improve glycemic measures and reduce total and abdominal fat in appropriate populations. But claims that they “reverse menopause insulin resistance” or selectively target menopause-related visceral fat go beyond the evidence. The STEP 1 DXA subgroup found reductions in total and regional visceral fat, along with a reduction in absolute lean mass; it was not designed around menopause (STEP 1 trial report).
GLP-1 Medications Do Not Treat Hot Flashes
Neither the Wegovy nor Zepbound label includes hot flashes, night sweats, or menopause as an indication. There is not established clinical-trial evidence that semaglutide or tirzepatide relieves vasomotor symptoms.
The FDA has approved hormone therapies for moderate-to-severe hot flashes and other menopause indications, including prevention of bone loss in appropriate patients. Benefits and risks depend on the product, route, age, time since menopause, and individual medical history (FDA menopause hormone-therapy update). Nonhormonal prescription options also exist. A clinician who treats menopause can help separate symptom treatment from weight treatment.
GLP-1 Medications and Hormone Therapy (HRT)
Using hormone therapy and a GLP-1-based medicine at the same time is not automatically the same as a drug interaction. However, “no known interactions” is too absolute.
Both Wegovy and Zepbound prescribing information state that the medicines delay gastric emptying and may affect absorption of some oral medications. Zepbound carries a specific precaution for oral hormonal contraceptives after starting treatment and after dose increases; contraceptives are not the same as menopause hormone therapy. The practical point is to review all oral medicines—including oral HRT—with a prescriber or pharmacist rather than assume every formulation is unaffected.
A 2024 Mayo Clinic record review compared 106 postmenopausal semaglutide users: 16 were using systemic hormone therapy and 90 had never used it. The hormone-therapy group lost more weight, but this small, retrospective study can show only an association. It does not prove that HRT boosts semaglutide, and it is not a reason to start HRT for weight loss (Menopause).
HRT decisions should instead focus on menopause symptoms, bone health, contraindications, and personal preferences. The choice also depends on whether a person has a uterus and whether treatment is systemic or local.
Muscle and Bone Health During Weight Loss
Menopause and weight loss can both make body-composition monitoring more important. In STEP 1, semaglutide reduced fat mass, but absolute lean mass also fell. “Lean mass” is not identical to muscle, and the clinical meaning varies, yet the result supports taking muscle preservation seriously rather than focusing only on scale weight.
Bone evidence is less settled. The 64-person fracture-risk trial found more bone resorption and lower bone mass at some sites with semaglutide after 52 weeks. The authors noted that this might reflect reduced mechanical loading from weight loss, a direct drug effect, or both. The study was not designed to determine fracture risk, so fracture outcomes during obesity treatment remain uncertain.
Practical topics to discuss with a clinician or dietitian include:
- enough protein and total nutrition despite reduced appetite;
- resistance and weight-bearing exercise suited to your health and mobility;
- calcium and vitamin D needs based on diet, laboratory results, and risk—not automatic megadoses;
- whether age, prior fractures, early menopause, steroid use, or other risk factors warrant bone-density testing; and
- avoiding overly rapid loss when side effects or low intake make it hard to maintain strength.
See our exercise guide and fatigue and energy guide for related planning.
Side Effects That Can Overlap With Midlife Symptoms
Nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue are among the adverse effects listed for GLP-1-based weight medicines. Dehydration or inadequate intake can worsen dizziness, fatigue, or a general feeling of being unwell. Those experiences can occur alongside hot flashes or sleep disruption, but one does not prove the other is caused by the medication.
Hair shedding can occur after substantial weight loss or nutritional stress and may overlap with age- or hormone-related hair changes. Read more in our GLP-1 hair-loss guide.
Seek prompt medical guidance for severe or persistent symptoms, inability to keep fluids down, severe abdominal pain, or symptoms listed as urgent in your medication guide.
Questions to Ask Your Clinician
- Do I meet an approved indication for this medication independent of menopause?
- Are my symptoms more likely related to menopause, medication effects, sleep, thyroid disease, anemia, or another condition?
- Could delayed gastric emptying matter for any of my oral medicines, including HRT?
- What is the plan to preserve muscle and support bone health during weight loss?
- Should my weight-loss and menopause treatments be monitored by the same clinician or a coordinated team?
- What should trigger a dose adjustment, pause, or urgent evaluation?
If pregnancy is still possible during perimenopause, menopause symptoms and irregular periods do not guarantee infertility. Review contraception and pregnancy plans before treatment; see our GLP-1 fertility and pregnancy guide and GLP-1 birth-control guide.
Bottom Line
GLP-1-based medicines can be effective obesity treatments for eligible people before, during, and after the menopause transition. Current evidence does not show that they treat menopause, restore estrogen, or relieve hot flashes. Menopause-specific research remains thinner than general obesity research, and observational findings about combining semaglutide with HRT should not be treated as proof of synergy.
The most useful approach is to define separate goals: use evidence-based menopause care for vasomotor, vaginal, sleep, or bone concerns, and consider weight medication for an approved metabolic indication. Then build one coordinated plan that accounts for oral medications, nutrition, muscle, bone, side effects, and individual risk.
This article is for education and does not replace medical advice. Medication and hormone-therapy decisions should be made with a qualified clinician who knows your history.
